Levosert

Levonorgestrel, the active ingredient in Levosert, is a progestin presented as a 52 mg intrauterine system for intrauterine use. It provides long‑acting reversible contraception and prevents pregnancy for up to five years.

GNH USA supplies Levosert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levosert, a hormonal contraceptive delivered via an intrauterine system, is indicated for:

- Long‑acting reversible contraception: provides up to five years of reliable pregnancy prevention. - Prevention of unintended pregnancy: suitable for women seeking a non‑daily, highly effective method. - Management of menstrual bleeding patterns: may reduce heavy or irregular bleeding in many users.

Levosert may cause a range of adverse reactions. Most are mild and resolve with time.

Common Side Effects: - Irregular bleeding or spotting, especially during the first months. - Amenorrhea (absence of periods) after continued use. - Pelvic or uterine cramping. - Breast tenderness or mild hormonal symptoms. - Headache or mild nausea.

Serious or Rare Side Effects: - Uterine perforation during insertion. - Expulsion of the device. - Pelvic infection (e.g., PID) following placement. - Ectopic pregnancy if contraception fails. - Rare systemic hormonal effects such as thrombosis.

Before insertion of Levosert, certain precautions should be observed to ensure safety and effectiveness.

- Screen for contraindications: ensure the patient has no active pelvic infection, unexplained vaginal bleeding, or known hypersensitivity to levonorgestrel. - Assess uterine anatomy: appropriate for a normal uterine cavity size and shape. - Confirm non‑pregnancy: a negative pregnancy test is required prior to placement. - Monitor device position: schedule follow‑up visits to check for displacement or expulsion. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Levosert may interact with medications that affect levonorgestrel metabolism or hormone levels.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine, phenytoin): may significantly reduce contraceptive efficacy. - Certain antiretroviral protease inhibitors: can alter hormone concentrations and compromise effectiveness.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers (e.g., St. John’s wort, efavirenz): may modestly lower levonorgestrel levels. - Antifungal azoles and some antibiotics (e.g., griseofulvin): could affect hormone metabolism and require additional contraceptive measures. - Concurrent hormonal therapies (e.g., estrogen‑containing contraceptives): may increase overall hormonal exposure and warrant clinical review.